Loading
A phase 2 trial of Inavolisib, Ribociclib and Fulvestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer is a phase 2 interventional study registered as NCT07405801 by Hoffmann-La Roche, with 80 participants planned, started 2026-04-07 and due to reach its primary completion in 2028-12-19. Interventions recorded: Inavolisib, Ribociclib, Fulvestrant and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Fulvestrant and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Fulvestrant and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Ribociclib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/